The news: Pfizer and Bristol Myers Squibb will launch a direct-to-patient channel to sell their blockbuster blood thinner Eliquis at a reduced cash-pay price. Our take: Pfizer and Bristol Myers Squibb have anticipated the Eliquis patent loss and sales drop for years as part of the typical branded drug cycle. We see the new direct sales platform launch not as a play for new revenues, but rather a negotiating nod to the Trump administration. Only 10% of Eliquis patients are uncovered by insurance, so it’s a small market to court as a revenue-driving ploy. However, Trump has made it clear he’s open to using any levers possible to force lower drug prices, pushing pharma companies to offer good faith options and concessions.
The news:. A new report reviewed by STAT reveals that Pfizer and Eli Lilly pay their telehealth provider partners upwards of a few million dollars. Our take: Drugmakers in the D2C telehealth market likely won’t be too worried about the report’s findings. It will be difficult for regulators to prove that a pharma company’s payment to a telehealth partner is directly tied to prescription volume. Drug brands will need to boost awareness of their D2C offerings to justify the price they pay telehealth firms, however.
The news: UnitedHealth Group has been engaging in a series of legal tactics to silence some of the company’s loudest critics, according to a recent NYT report. Our take: UnitedHealth is more focused on defending its business than acknowledging people’s concerns and offering solutions. This won’t do anything to help its brand reputation—but that probably isn’t a major concern for UnitedHealth right now. Similar to drugmakers, health insurers recognize that healthcare is not like a typical D2C industry, in which consumer experience is the most important measure of success.
On today’s podcast episode, we discuss the weight-loss drugs revolution: how they work, their efficacy, how they became so popular, and how they’re reshaping multiple industries. Join Senior Director of Podcasts and host Marcus Johnson and Senior Analysts Rajiv Leventhal and Beth Snyder Bulik. Listen everywhere and watch on YouTube and Spotify.
The news: Pharma companies can earn a speedier path to approvals for new drugs if they agree to lower US prices to global levels. The takeaway: Pharma companies are on board with faster drug approvals and higher global prices, but they still make the bulk of their profits on US sales. By adopting good faith balanced stances—advocating for fairer pricing, but highlighting innovation—pharma can notch wins with the administration and consumers.
The news: President Trump is threatening 200% tariffs on pharma products, but the 1+ year lag in enforcement gives drugmakers time to increase US manufacturing. Our take: While 200% is an exorbitant tariff rate, the year-long reprieve is a win for drugmakers. It gives them time to move product and double down on US manufacturing commitments, and also opens a big window for change with the capricious Trump administration.
The news: Hims & Hers will soon expand its business to Canada, where it plans to sell generic semaglutide. The bottom line: Novo just gave a massive gift to healthcare companies that are in the weight loss drug market but can no longer sell compounded GLP-1s now that the brand-name versions are available again. We’ll likely see more players in this space that primarily operate in the US expanding north of the border, while others could take advantage of President Trump’s executive order that calls for the FDA to authorize more states to import lower-cost drugs from Canada.
The news: Mattel introduced the first Barbie doll with type 1 diabetes, sporting a glucose monitor and insulin pump. Our take: Pharma insulin makers like Sanofi, Eli Lilly, and Novo Nordisk, and device companies like Dexcom, Abbott, and Medtronic can leverage the type 1 Barbie news to drive more awareness and visibility and dispel stigma and the embarrassment kids with diabetes may feel.
The news: Healthline Media settled with the California Attorney General’s office over allegations that Healthline.com failed to opt consumers out of having their personal information shared for targeted advertising. Our take: State health data privacy laws are new, meaning we will likely see increased scrutiny and more enforcement action against companies that previously went unchecked. Healthline and other health content companies must verify that their opt-out tools work as intended while being transparent with advertisers about the consumer data they can and cannot share with them.
The news: Several leading medical associations representing hundreds of thousands of US clinicians, as well as scientists, researchers, and public health workers, have sued HHS Secretary Robert F. Kennedy Jr. and other top health officials over the government’s recent decision to make COVID-19 vaccines more restrictive. The big takeaway: Kennedy is running out of allies in the medical and pharma communities. If nothing else, the lawsuit could force Kennedy and his team to adhere to the legal framework in place for making sudden changes that disrupt the public’s access to vaccines.
The news: Spain is investigating Novo Nordisk over a controversial obesity awareness ad campaign tied to its weight loss drugs. Our take: GLP-1 weight loss drugs are in demand, but drugmakers can’t afford any trust gaps with health systems and physicians in the competitive race for customers.
The news: Here’s a look back at the most popular stories from January through June 2025. The final word: Gen Z’s healthcare attitudes, social health influencers, marketing strategies, and how patients use AI drew the most attention from our audience.
The news: A Microsoft AI pilot study showed a fourfold improvement in diagnostics compared with a panel of real doctors, but researchers acknowledged the continued need for human expertise. The takeaway: It’s evident AI is not a replacement for doctors, but it is a tool they should start adopting. There’s a window of opportunity for doctors and healthcare systems to grab a first-mover advantage by presenting AI as a co-pilot and a value-add that leads to more accurate diagnoses and more time spent with patients.
63% of millennials and 61% of Gen Zers feel more connected to health brands since starting GLP-1s, per a January Dentsu report.
The news: Novo Nordisk is partnering with WeightWatchers to offer discounted Wegovy to cash-pay customers. Our take: WeightWatchers is recognizing that diet culture is being replaced by weight loss medications accessible via virtual care. To stand out from other Novo’s other telehealth partners, WeightWatchers should lean into marketing that positions the company as a pioneer weight loss brand that’s now meeting consumer demand for GLP-1s.
The news: Consumers who are more familiar with AI are also more likely to mistrust an AI-assisted diagnosis from their doctor, per a recently published Journal of Medical Internet Research survey. Our take: Physicians and healthcare marketers can’t assume people who are familiar with AI will be more comfortable with AI uses in healthcare. Marketers need to talk about AI as a tool with many positive effects like freeing doctors for longer personal interactions and resulting in fewer mistakes.
The trend: US consumers trust the pharma companies that advertise the prescription drugs they’re taking. Our take: Pharma companies can take heart in knowing the people who take their drugs trust them and their advertising. But it’s also an opportunity for precise data and media targeting to reach new consumers who would be interested in their medication—undiagnosed people or competitors’ patients—and receptive to learning about them.
The trend: Over three-quarters of US hospitals now task pharmacists with patient care responsibilities, according to a recently published survey from the American Society of Health System Pharmacists. Our take: Struggling retail pharmacies should also entrust pharmacists to play a bigger role in patient care, especially as some drugstores pivot to health-focused store formats.
The news: A majority of GLP-1 weight loss drug consumers are now staying on the medications for more than a year, per an annual Prime Therapeutics analysis. The Prime study includes 5,780 people via healthcare claims over three years; the mean age was 47 and 80% were women. The final word: Adherence rates longer than a year validates the idea that prescription weight loss GLP-1s, and newer drugs on the way, are here to stay as chronic disease treatments. It shifts typical weight loss marketing from cyclical—keep your New Year’s resolution or lose weight for your wedding—to medical and consistent.
The news: Novo Nordisk is terminating its short-lived partnership with Hims & Hers. The drugmaker is accusing Hims of illegally selling knockoff versions of Wegovy, while deceptively marketing its compounded GLP-1 products. Our take: Hims will likely regret its refusal to cooperate with Novo and Eli Lilly, who have taken control of the D2C weight loss drug market.
One Liberty Plaza9th FloorNew York, NY 100061-800-405-0844
1-800-405-0844sales@emarketer.com